Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLS-005 open-label phase 2 basket study in ALS, Huntington's disease, and SCA3
ACTRN12621001755820Phase 2Not yet recruiting
- Sponsor
- Avance Clinical
- Start
- Dec 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trehalose in amyotrophic lateral sclerosis (ALS), Huntington disease (HD) and machado-joseph disease (MJD), sponsored by Avance Clinical. Primary endpoints: Safety and tolerability of SLS-005 and Treatment response rate by PGIC and CGIC. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
trehalose
03
Conditions
amyotrophic lateral sclerosis (ALS)Huntington disease (HD)machado-joseph disease (MJD)
Beyond the preview
Go deeper on ACTRN12621001755820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001755820.